TY - JOUR
T1 - The role of checkpoint inhibitors in paraneoplastic acute exudative polymorphous vitelliform maculopathy
T2 - report of two cases
AU - Kemels, Dieter
AU - Ten Berge, Josianne Carina Elvire Maria
AU - Jacob, Julie
AU - Schauwvlieghe, Pieter Paul
N1 - Publisher Copyright:
© by Ophthalmic Communications Society, Inc. Unauthorized reproduction of this article is prohibited.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Purpose:To report on two cases with paraneoplastic acute exudative polymorphous vitelliform maculopathy within one month after the initiation of nivolumab. Methods:Case report. Results:Two patients with metastatic mucosal melanoma were diagnosed with acute exudative polymorphous vitelliform maculopathy within one month after the initiation of the checkpoint inhibitor nivolumab. Both cases showed a neurosensory retinal detachment and subretinal hyperautofluorescent material, which persisted after discontinuation of nivolumab and treatment with local and/or systemic corticosteroids. In one case, nivolumab was introduced again in a later stage in combination with surgical reduction of the tumor, eventually leading to resolution of the subretinal lipofuscin-rich fluid.Conclusion:The development of paraneoplastic acute exudative polymorphous vitelliform maculopathy in melanoma patients can be triggered by treatment with nivolumab. However, achieving tumor control, which may involve continuation of nivolumab, could be the key to success.
AB - Purpose:To report on two cases with paraneoplastic acute exudative polymorphous vitelliform maculopathy within one month after the initiation of nivolumab. Methods:Case report. Results:Two patients with metastatic mucosal melanoma were diagnosed with acute exudative polymorphous vitelliform maculopathy within one month after the initiation of the checkpoint inhibitor nivolumab. Both cases showed a neurosensory retinal detachment and subretinal hyperautofluorescent material, which persisted after discontinuation of nivolumab and treatment with local and/or systemic corticosteroids. In one case, nivolumab was introduced again in a later stage in combination with surgical reduction of the tumor, eventually leading to resolution of the subretinal lipofuscin-rich fluid.Conclusion:The development of paraneoplastic acute exudative polymorphous vitelliform maculopathy in melanoma patients can be triggered by treatment with nivolumab. However, achieving tumor control, which may involve continuation of nivolumab, could be the key to success.
UR - http://www.scopus.com/inward/record.url?scp=85103264258&partnerID=8YFLogxK
U2 - 10.1097/ICB.0000000000001040
DO - 10.1097/ICB.0000000000001040
M3 - Article
C2 - 32740323
AN - SCOPUS:85103264258
SN - 1935-1089
VL - 16
SP - 614
EP - 618
JO - Retinal Cases and Brief Reports
JF - Retinal Cases and Brief Reports
IS - 5
ER -